Skip to main content
Erschienen in: Intensive Care Medicine 11/2011

Open Access 01.11.2011 | Correspondence

Cystatin C is not a reliable marker of residual glomerular filtration rate during continuous renal replacement therapy

verfasst von: H. D. Kiers, R. de Sévaux, P. Pickkers

Erschienen in: Intensive Care Medicine | Ausgabe 11/2011

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
An author’s reply to this comment is available at: doi:10.​1007/​s00134-011-2348-4.
Dear Editor,
With interest we read the recent observational cohort study by Royakkers et al. [1] that shows that higher levels of cystatin C do not predict the development of acute kidney injury (AKI) nor the need for renal replacement therapy (RRT). Apart from the hypothesis that cystatin C could detect AKI 1 or 2 days earlier than serum creatinine, which was not confirmed in the study by Royakkers, it is also thought that serum cystatin C is less influenced by RRT than creatinine, and thus better reflects residual glomerular filtration rate (GFR). Determining residual GFR is difficult to establish in the critically ill patient with no steady state in renal function and large changes in fluid balance.
As creatinine is a small-sized molecule that is eliminated from the blood during RRT, it is not useful for estimating the residual GFR. Cystatin C is a medium-sized molecule (13.3 kDa). Calculated from measurements in the efferent and afferent line and from the ultrafiltrate line, it has been shown that the removal of cystatin C by continuous venovenous hemofiltration (CVVH) is less than 30% of its generation and is therefore thought not to influence serum cystatin C significantly. Although the reduction ratio of cystatin C is dependent on the type of membrane, dialysis dose, volume, and ultrafiltration rate, it is advocated that cystatin C can be used to estimate the residual GFR in patients on RRT [2]. Importantly, changes in serum cystatin C were not determined in this study.
We determined serum creatinine and cystatin C in 6 patients with septic shock with AKI 48 and 24 h prior and following the initiation of CVVH. CVVH was performed using the Prismaflex (Gambro) system with an AN100 ST filter (polyacrylonitrile), a blood flow of 200 ml/min, and a predilution substitution flow of 2,000 ml/h. CVVH was started according to the criteria for initiation of RRT that were standardized by the Acute Dialysis Quality Initiative (ADQI) consensus [3].
We compared the serum creatinine and cystatin C at initiation and after 24 h of CVVH with a paired Student’s t test. We observed that serum cystatin C decreased significantly following initiation of CVVH (p = 0.04), whereas the decrease of serum creatinine within the first 24 h was not significant (ns, p = 0.66), as shown in Fig. 1.
This observation was previously described in patients that received intermittent hemodialysis; a higher dose of dialysis resulted in a decreased level of serum cystatin C, indicating that dialysis removes cystatin C from the patient [4]. In a previous study, 3 h of intermittent hemodialysis using a polymethylmethacrylate filter decreased cystatin C concentrations by 30 ± 7% [5]. This supports the hypothesis that in different types of renal replacement therapy serum cystatin C concentrations are reduced.
In addition to the inability of cystatin C to predict AKI better or earlier than serum creatinine, our finding highlights the limited value of cystatin C in assessing residual GFR in patients with sepsis-induced AKI.

Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
Open AccessThis is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (https://​creativecommons.​org/​licenses/​by-nc/​2.​0), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
download
DOWNLOAD
print
DRUCKEN

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

e.Med Anästhesiologie

Kombi-Abonnement

Mit e.Med Anästhesiologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes AINS, den Premium-Inhalten der AINS-Fachzeitschriften, inklusive einer gedruckten AINS-Zeitschrift Ihrer Wahl.

Literatur
1.
Zurück zum Zitat Royakkers AA, Korevaar JC, van Suijlen JD, Hofstra LS, Kuiper MA, Spronk PE, Schultz MJ (2011) Serum and urine cystatin C are poor biomarkers for acute kidney injury and renal replacement therapy. Intensive Care Med 37:493–501PubMedCrossRef Royakkers AA, Korevaar JC, van Suijlen JD, Hofstra LS, Kuiper MA, Spronk PE, Schultz MJ (2011) Serum and urine cystatin C are poor biomarkers for acute kidney injury and renal replacement therapy. Intensive Care Med 37:493–501PubMedCrossRef
2.
Zurück zum Zitat Baas MC, Bouman CS, Hoek FJ, Krediet RT, Schultz MJ (2006) Cystatin C in critically ill patients treated with continuous venovenous hemofiltration. Hemodial Int 10(Suppl 2):S33–S37PubMedCrossRef Baas MC, Bouman CS, Hoek FJ, Krediet RT, Schultz MJ (2006) Cystatin C in critically ill patients treated with continuous venovenous hemofiltration. Hemodial Int 10(Suppl 2):S33–S37PubMedCrossRef
3.
Zurück zum Zitat Bellomo R, Angus D, Star RA (2002) The acute dialysis quality initiative–part II: patient selection for CRRT. Adv Ren Replace Ther 9:255–259PubMedCrossRef Bellomo R, Angus D, Star RA (2002) The acute dialysis quality initiative–part II: patient selection for CRRT. Adv Ren Replace Ther 9:255–259PubMedCrossRef
4.
Zurück zum Zitat Al-Malki N, Heidenheim PA, Filler G, Yasin A, Lidnsay RM (2009) Cystatin C levels in functionally anephric patients undergoing dialysis: the effect of different methods and intensities. Clin J Am Soc Nephrol 4:1606–1610PubMedCrossRef Al-Malki N, Heidenheim PA, Filler G, Yasin A, Lidnsay RM (2009) Cystatin C levels in functionally anephric patients undergoing dialysis: the effect of different methods and intensities. Clin J Am Soc Nephrol 4:1606–1610PubMedCrossRef
5.
Zurück zum Zitat Mayeur N, Rostaing L, Nogier MB, Jaafar A, Cointault O, Kamar N, Conil JM, Fourcade O (2010) Kinetics of plasmatic cytokines and cystatin C during and after hemodialysis in septic shock-related acute renal failure. Crit Care 14:R115PubMedCrossRef Mayeur N, Rostaing L, Nogier MB, Jaafar A, Cointault O, Kamar N, Conil JM, Fourcade O (2010) Kinetics of plasmatic cytokines and cystatin C during and after hemodialysis in septic shock-related acute renal failure. Crit Care 14:R115PubMedCrossRef
Metadaten
Titel
Cystatin C is not a reliable marker of residual glomerular filtration rate during continuous renal replacement therapy
verfasst von
H. D. Kiers
R. de Sévaux
P. Pickkers
Publikationsdatum
01.11.2011
Verlag
Springer-Verlag
Erschienen in
Intensive Care Medicine / Ausgabe 11/2011
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-011-2346-6

Weitere Artikel der Ausgabe 11/2011

Intensive Care Medicine 11/2011 Zur Ausgabe

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Delir bei kritisch Kranken – Antipsychotika versus Placebo

16.05.2024 Delir Nachrichten

Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.